Search Medical Condition
Please enter condition
Please choose location from dropdown

Hoegaarden, Belgium Clinical Trials

A listing of Hoegaarden, Belgium clinical trials actively recruiting patients volunteers.

RESULTS

Found (26) clinical trials

Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)

To characterize dose response, and evaluate safety and efficacy of three different doses of EMA401 compared to placebo in patients with post-herpetic neuralgia (PHN)

Phase

8.58 miles

Learn More »

Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)

The purpose of this study is to evaluate safety and efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN).

Phase

8.58 miles

Learn More »

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

Givinostat or placebo oral suspension (10 mg/mL) will be administered orally as 2 oral doses daily while the subject is in fed state, according to the child's weight. Study drug should be permanently stopped if any of the following occur: severe drug-related diarrhoea; any drug-related Serious Adverse Event; QTcF >500 ...

Phase

9.04 miles

Learn More »

Dose Escalation Study of QR-010 in Homozygous F508 Cystic Fibrosis Patients

The purpose of this study is to evaluate the safety, tolerability, and to determine the pharmacokinetics of QR-010 administered via inhalation in adult homozygous for ΔF508 Cystic Fibrosis.

Phase

9.04 miles

Learn More »

A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors

NKTR-214 is a cytokine (investigational agent) that is designed to target CD122, a protein which is found on certain immune cells (known as CD8+ T Cells and Natural Killer Cells) to expand these cells to promote their anti-tumor effects. Nivolumab is a full human monoclonal antibody that binds to a ...

Phase

9.04 miles

Learn More »

Home basEd faecaL calProtectin Measurements Predicting Adalimumab Induction Destiny

Adalimumab (Humira), a fully human monoclonal antibody to TNF, has been given an important position in the treatment of patients with an inflammatory bowel disease (IBD). However, not all patients respond adequately to this relatively expensive and potentially toxic therapy. Adapting the standard treatment regimen to the individual needs of ...

Phase N/A

9.04 miles

Learn More »